Affiliation:
1. Drug Discovery Research, Astellas Pharma Inc.
Publisher
Pharmaceutical Society of Japan
Subject
Pharmaceutical Science,Pharmacology,General Medicine
Reference52 articles.
1. 1) Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med., 380, 2295–2306 (2019).
2. 2) McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 381, 1995–2008 (2019).
3. 3) Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med., 383, 1413–1424 (2020).
4. 4) Pabel S, Hamdani N, Luedde M, Sossalla S. SGLT2 Inhibitors and their mode of action in heart failure-has the mystery been unravelled? Curr. Heart Fail. Rep., 18, 315–328 (2021).
5. 5) Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61, 2108–2117 (2018).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献